150 related articles for article (PubMed ID: 27031354)
21. A comparative study of protein patterns of human estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cell lines.
Flodrova D; Toporova L; Macejova D; Lastovickova M; Brtko J; Bobalova J
Gen Physiol Biophys; 2016 Jul; 35(3):387-92. PubMed ID: 27174898
[TBL] [Abstract][Full Text] [Related]
22. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
[TBL] [Abstract][Full Text] [Related]
23. CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer--Where Did It Start and Where Are We Now?
Gingras I; Desmedt C; Ignatiadis M; Sotiriou C
Clin Cancer Res; 2015 Nov; 21(21):4743-6. PubMed ID: 26527804
[TBL] [Abstract][Full Text] [Related]
24. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
Colomer R; Aranda-López I; Albanell J; García-Caballero T; Ciruelos E; López-García MÁ; Cortés J; Rojo F; Martín M; Palacios-Calvo J
Clin Transl Oncol; 2018 Jul; 20(7):815-826. PubMed ID: 29273958
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiling in breast cancer: a clinical perspective.
Arpino G; Generali D; Sapino A; Del Matro L; Frassoldati A; de Laurentis M; Pronzato P; Mustacchi G; Cazzaniga M; De Placido S; Conte P; Cappelletti M; Zanoni V; Antonelli A; Martinotti M; Puglisi F; Berruti A; Bottini A; Dogliotti L
Breast; 2013 Apr; 22(2):109-120. PubMed ID: 23462680
[TBL] [Abstract][Full Text] [Related]
26. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
[TBL] [Abstract][Full Text] [Related]
27. Molecular signatures in breast cancer.
Lal S; McCart Reed AE; de Luca XM; Simpson PT
Methods; 2017 Dec; 131():135-146. PubMed ID: 28669865
[TBL] [Abstract][Full Text] [Related]
28. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?
Lee JJ; Shen J
Am Surg; 2011 Oct; 77(10):1364-7. PubMed ID: 22127090
[TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
Yang M; Rajan S; Issa AM
Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
[TBL] [Abstract][Full Text] [Related]
30. Expression of TRAG-3 in breast cancer.
Wu YZ; Zhao TT; Ni B; Zou LY; Liu HL; Zhu B
Int J Cancer; 2003 Oct; 107(1):167-8. PubMed ID: 12925976
[No Abstract] [Full Text] [Related]
31. A disease annotation study of gene signatures in a breast cancer microarray dataset.
Gypas F; Bei ES; Zervakis M; Sfakianakis S
Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():5551-4. PubMed ID: 22255596
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
[TBL] [Abstract][Full Text] [Related]
33. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
[TBL] [Abstract][Full Text] [Related]
34. An Integrative Approach for Identifying Network Biomarkers of Breast Cancer Subtypes Using Genomic, Interactomic, and Transcriptomic Data.
Firoozbakht F; Rezaeian I; D'agnillo M; Porter L; Rueda L; Ngom A
J Comput Biol; 2017 Aug; 24(8):756-766. PubMed ID: 28650678
[TBL] [Abstract][Full Text] [Related]
35. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.
Williams DJ; Cohen C; Darrow M; Page AJ; Chastain B; Adams AL
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):431-6. PubMed ID: 21297447
[TBL] [Abstract][Full Text] [Related]
36. Clinical implications of the intrinsic molecular subtypes of breast cancer.
Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
[TBL] [Abstract][Full Text] [Related]
37. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
Milburn M; Rosman M; Mylander C; Tafra L
Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
[TBL] [Abstract][Full Text] [Related]
38. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
39. Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests.
Jahn SW; Bösl A; Tsybrovskyy O; Gruber-Rossipal C; Helfgott R; Fitzal F; Knauer M; Balic M; Jasarevic Z; Offner F; Moinfar F
Br J Cancer; 2020 Jun; 122(12):1744-1746. PubMed ID: 32336753
[TBL] [Abstract][Full Text] [Related]
40. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
